QIAGEN’s US$2.09bn year and buyout talk, Sanquin’s record 421 tonnes of plasma, Philips’ scanner plant in Best and the EMA in Amsterdam: the Dutch diagnostics sector explained.
Startup · Topic
Netherlands Health & Life Sciences
Expert guides, analysis and tool comparisons on Netherlands Health & Life Sciences from the kurums.com Startup desk — written for business decision-makers and updated as the market moves.
- 5 guides
- Updated Oct 20, 2026
Latest in Netherlands Health & Life Sciences
How Dutch Healthcare Works: Mandatory Private Insurers, Price Caps and Record Costs
Mandatory private insurance, four dominant insurers, a €158.77 average premium and a deductible rising to €400: how the Dutch healthcare model works and where it strains in 2026.
Galapagos, argenx and the Dutch-Belgian Biotech Corridor: Boom, Bust and an US$8bn Exit
argenx’s Vyvgart hit US$4.2bn in sales, Galapagos wound down and became Lakefront, Genmab bought Merus for US$8bn. Inside the Leiden-Ghent-Mechelen biotech corridor.
DSM-Firmenich: From Dutch State Mines to a Swiss-Dutch Nutrition and Fragrance Group
DSM mined coal for the Dutch state in 1902. In 2026 dsm-firmenich is a Swiss-domiciled fragrance and nutrition group selling its last commodity business to CVC. The full story.
Philips After Respironics: How a Sleep-Apnoea Recall Shook a 130-Year-Old Dutch Icon
From the June 2021 CPAP recall to a 2024 consent decree and US$1.1bn settlement: what the Respironics crisis cost Philips and how Roy Jakobs’ turnaround is going in 2026.
All guides
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
